CRP including hsCRP
[CRP including hsCRP]
EPTIS factsheet 143122 | Last revision 2024-10-01 | URL: https://www.eptis.bam.de/pts143122 https://www.eptis.bam.de/pts143122
| PT provider | ||||||||||
| PT provider | Weqas Weqas | |||||||||
| Based in | United Kingdom | |||||||||
| Language(s) | ||||||||||
| Remarks | The standard (CRP) test is a well-established marker for inflammation and infection. The measuring range being approximately 10 to 1000 mg/L. However, low but persistent levels of inflammation is often associated with CVD. A high sensitivity CRP (hsCRP) test has been proposed as a marker to assess the individual’s risk of CVD. The hs-CRP test accurately detects much lower levels of the protein than the standard CRP test, range from 0.5 to 10 mg/L. Suitable for assessment of high sensitivity (hs) CRP and standard CRP assays. Three liquid human serum samples are distributed monthly with a minimum of 36 samples distributed over the year covering a wide clinically relevant range. The samples consist of endogenous samples from normal volunteers and patients to cover the clinical range for the (hs) CRP methods used for CVD risk assessment. The samples for the standard assay consist of endogenous patient samples along with a panel of linearly related samples produced from donations from healthy volunteers spiked with a highly purified source of human CRP to provide an extended clinical range. The programme assesses both laboratory and method performance, including bias, within and between batch imprecision and linearity. Key Features: - Commutable, endogenous samples. - Suitable for assessment of high sensitivity (hs) CRP and standard CRP assays. - Liquid human serum samples require no pre-analytical preparation. - Linearly related panel covering the pathological range. For more information: https://www.weqas.com/services/eqa/crp-including-hscrp/ or contact@weqas.com | |||||||||
| Keywords | ||||||||||
| Product groups |
Health care / medical devices
|
|||||||||
| Testing fields |
Medical analysis
|
|||||||||
| Technical details | ||||||||||
|
||||||||||
| Aims of the PT scheme | ||||||||||
| Target group of participants | The Programme aims to assess the performance of organisations utilising the standard C – reactive protein (CRP) test as a marker of infection and for those using hsCRP in the assessment of risk for Cardiovascular Disease (CVD). | |||||||||
| Linked to specific legislation / standards | ISO/IEC 17043 | |||||||||
| Additional, subsidiary aims | validation of testing methods | |||||||||
| Number of participants | ||||||||||
| Accredited or otherwise reviewed by a 3rd party |
Accredited by UKAS on the basis of ISO/IEC 17043 |
|||||||||
| Operation is commissioned / requested by | ||||||||||
| Fees and frequency | ||||||||||
| Participation fee | https://www.weqas.com/participantzone/subscription-charges/ | |||||||||
| Regularly operated | Yes (Frequency: Monthly. Samples: 3 x 0.5mL) | |||||||||
| Year of first operation | 2011 | |||||||||
| Contact details of the PT provider | ||||||||||
| Provider | Contact person | |||||||||
|
Weqas
Unit 6, Parc Ty Glas CF14 5DU Cardiff United Kingdom Phone: 44 (0) 2920 314750 Fax: Web: http://www.weqas.com http://www.weqas.com |
Laura Lloyd-Lewis
Phone: 44 (0) 29218 32884 Fax: Email: laura.lloyd-lewis@wales.nhs.uk laura.lloyd-lewis@wales.nhs.uk |
|||||||||
If you find any mistakes please contact the responsible EPTIS coordinator in United Kingdom,
Mr Savvas Xystouris.
Mr Savvas Xystouris.